{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:49:46Z","timestamp":1790524186140,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000046","name":"National Research Council Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["OVV 152411"],"award-info":[{"award-number":["OVV 152411"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.09.044","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T17:10:37Z","timestamp":1568999437000},"page":"6624-6632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-5781","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"G\u00e9linas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiva","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Kiesslich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Lanthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannie","family":"Perdersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder S.","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Ansorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Kobinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9nald","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-8815","authenticated-orcid":false,"given":"Amine A.","family":"Kamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.09.044_b0005","unstructured":"Situation Report \u2013 Ebola Virus Disease \u2013 10 June 2016. Geneva: World Health Organization; 2016."},{"key":"10.1016\/j.vaccine.2019.09.044_b0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijid.2018.06.022","article-title":"Ebola vaccine development: systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination","volume":"74","author":"Gross","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.044_b0015","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.09.044_b0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.09.044_b0025","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I\/II trial in healthy adults in Russia","volume":"13","author":"Dolzhikova","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.09.044_b0030","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.09.044_b0035","first-page":"313","article-title":"Vesicular stomatitis and its relation to the diagnosis of foot-and-mouth disease","volume":"69","author":"Cotton","year":"1926","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2019.09.044_b0040","first-page":"754","article-title":"Human infection with the virus of vesicular stomatitis","volume":"36","author":"Hanson","year":"1950","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.vaccine.2019.09.044_b0045","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM196711092771901","article-title":"Human infection with the virus of vesicular stomatitis during an epizootic","volume":"277","author":"Fields","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.09.044_b0050","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4269\/ajtmh.1966.15.244","article-title":"Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV)","volume":"15","author":"Johnson","year":"1966","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.vaccine.2019.09.044_b0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.aje.a121068","article-title":"Ecologic studies of vesicular stomatitis virus. I. Prevalence of infection among animals and humans living in an area of endemic VSV activity","volume":"90","author":"Tesh","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.09.044_b0060","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.044_b0065","doi-asserted-by":"crossref","first-page":"10194","DOI":"10.1128\/JVI.74.21.10194-10201.2000","article-title":"Functional importance of the coiled-coil of the Ebola virus glycoprotein","volume":"74","author":"Watanabe","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.044_b0070","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.09.044_b0075","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A Recombinant vesicular stomatitis Virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.09.044_b0080","doi-asserted-by":"crossref","first-page":"E819","DOI":"10.1503\/cmaj.170074","article-title":"Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial","volume":"189","author":"ElSherif","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2019.09.044_b0085","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.044_b0090","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.044_b0095","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/infdis\/jiy020","article-title":"The sierra leone trial to introduce a vaccine against ebola: an evaluation of rVSVG-ZEBOV-GP vaccine tolerability and safety during the west africa ebola outbreak","volume":"217","author":"Samai","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.044_b0100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.09.044_b0105","unstructured":"World Health Organisation. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: World Health Organisation; 2019."},{"key":"10.1016\/j.vaccine.2019.09.044_b0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12981-017-0179-2","article-title":"Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses","volume":"14","author":"Racine","year":"2017","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.vaccine.2019.09.044_b0115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-006-0042-3","article-title":"Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector","volume":"28","author":"Clarke","year":"2006","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.vaccine.2019.09.044_b0120","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.vaccine.2016.04.089","article-title":"Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: an effective influenza vaccine candidate","volume":"34","author":"Venereo-Sanchez","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.044_b0125","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1016\/j.vaccine.2016.04.090","article-title":"Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate","volume":"34","author":"Shen","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.044_b0130","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jbiotec.2013.05.001","article-title":"Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium","volume":"166","author":"Cervera","year":"2013","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2019.09.044_b0135","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1021\/bp000098l","article-title":"293SF metabolic flux analysis during cell growth and infection with an adenoviral vector","volume":"16","author":"Nadeau","year":"2000","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.vaccine.2019.09.044_b0140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jviromet.2013.10.038","article-title":"Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery","volume":"196","author":"Chahal","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.09.044_b0145","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.mt.6300383","article-title":"Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture","volume":"16","author":"Broussau","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2019.09.044_b0150","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/hgtb.2017.086","article-title":"Scalable lentiviral vector production using stable HEK293SF producer cell lines","volume":"28","author":"Manceur","year":"2017","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.vaccine.2019.09.044_b0155","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/biot.201500176","article-title":"Rational plasmid design and bioprocess optimization to enhance recombinant adeno-associated virus (AAV) productivity in mammalian cells","volume":"11","author":"Emmerling","year":"2016","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2019.09.044_b0160","unstructured":"Gilbert R, Coulombe N, Venne M, Lanthier S, Jacob D, Massariol M, et al. 327. A simple and robust process to scale-up lentiviral vector production by transient transfection of suspension cell culture in stirred-tank bioreactors. ASGCT 21st Annual Meeting. 2018;26:153\u20134."},{"key":"10.1016\/j.vaccine.2019.09.044_b0165","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0290(19980905)59:5<567::AID-BIT6>3.0.CO;2-8","article-title":"Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells","volume":"59","author":"Cote","year":"1998","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2019.09.044_b0170","first-page":"2051","article-title":"Replication and supercoiling of simian virus 40 DNA in cell extracts from human cells","volume":"5","author":"Stillman","year":"1985","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.vaccine.2019.09.044_b0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"Graham","year":"1977","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.09.044_b0180","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jviromet.2013.05.015","article-title":"Comparison of the plaque assay and 50% tissue culture infectious dose assay as methods for measuring filovirus infectivity","volume":"193","author":"Smither","year":"2013","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.09.044_b0185","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jgm.1370","article-title":"Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures","volume":"11","author":"Ansorge","year":"2009","journal-title":"J Gene Med"},{"key":"10.1016\/j.vaccine.2019.09.044_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2019.07.003","article-title":"Development of suspension adapted Vero cell culture process technology for production of viral vaccines","author":"Shen","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.044_b0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"10.1016\/j.vaccine.2019.09.044_b0200","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jbiotec.2018.11.023","article-title":"Optimization of production of vesicular stomatitis virus (VSV) in suspension serum-free culture medium at high cell density","volume":"289","author":"Elahi","year":"2019","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2019.09.044_b0205","unstructured":"Blue JT. Development, manufacturing, and supply of MSD\u2019s Ebola vaccine. Vaccine Technology VI. Albufeira, Portugal; 2016."},{"key":"10.1016\/j.vaccine.2019.09.044_b0210","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0734-9750(02)00030-7","article-title":"Production of adenovirus vector for gene therapy","volume":"20","author":"Nadeau","year":"2003","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2019.09.044_b0215","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/hum.2010.159","article-title":"Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment","volume":"22","author":"Ausubel","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2019.09.044_b0220","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1128\/JVI.77.16.8843-8856.2003","article-title":"Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity","volume":"77","author":"Obuchi","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.044_b0225","doi-asserted-by":"crossref","first-page":"e106597","DOI":"10.1371\/journal.pone.0106597","article-title":"A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice","volume":"9","author":"Rabinovich","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.09.044_b0230","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.78.8.3930-3940.2004","article-title":"Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol","volume":"78","author":"Ramsburg","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.044_b0235","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1128\/JVI.72.6.4704-4711.1998","article-title":"Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge","volume":"72","author":"Roberts","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.044_b0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2011.12.005","article-title":"Kinetics of virus production from single cells","volume":"424","author":"Timm","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.09.044_b0245","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J Virol Methods"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:15:32Z","timestamp":1777536932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19312538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":49,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X19312538"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}